Inhibrx promotes David Matly to President; CSO Eckelman resigns

Inhibrx Biosciences, Inc.

David J. Matly appointed President effective April 1, 2025, adding to his role as EVP, Chief Commercial and Business Development Officer.
Mark Lappe remains CEO and Chair but no longer holds President title; Matly's base salary increased to $601,670.
Matly granted 50,000 stock options vesting over four years under the company's equity plan.
Brendan P. Eckelman resigned as EVP, Chief Scientific Officer effective March 31, 2025, to found a new private biotech.
Company accelerated vesting of 50,000 of Eckelman's outstanding options and extended post-termination exercise period to October 1, 2026.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Mark Lappe

Chief Executive Officer and Chairperson of the Board

INBX · Inhibrx Biosciences, Inc.

Effective: 2025-04-01
Successor: David J. Matly
Filed: April 1, 2025, 7:59 PM ET

Mark Lappe will continue in his roles as Chief Executive Officer and Chairperson of the Board of Directors, but will no longer hold the title of President.

Appointed

David J. Matly

President

INBX · Inhibrx Biosciences, Inc.

Effective: 2025-04-01
Filed: April 1, 2025, 7:59 PM ET

On April 1, 2025, Inhibrx Biosciences, Inc. (the “Company”) announced the appointment of David J. Matly, M.B.A. as President, effective April 1, 2025, adding to his current role as Chief Commercial and Business Development Officer.

Departed

Brendan P. Eckelman

EVP, Chief Scientific Officer

INBX · Inhibrx Biosciences, Inc.

Effective: 2025-03-31
Filed: April 1, 2025, 7:59 PM ET

On March 31, 2025, Brendan P. Eckelman, Ph.D. informed the Company of his intention to resign as EVP, Chief Scientific Officer of the Company, effective immediately, to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Lappe changed role as Chief Executive Officer and Chairperson of the Board at Inhibrx Biosciences, Inc..

Action: relinquished President title
Role: Chief Executive Officer and Chairperson of the Board

Exact text from the filing

Mark Lappe will continue in his roles as Chief Executive Officer and Chairperson of the Board of Directors, but will no longer hold the title of President.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David J. Matly was appointed as President at Inhibrx Biosciences, Inc..

Action: appointed
Role: President

Exact text from the filing

On April 1, 2025, Inhibrx Biosciences, Inc. (the “Company”) announced the appointment of David J. Matly, M.B.A. as President, effective April 1, 2025, adding to his current role as Chief Commercial and Business Development Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan P. Eckelman resigned as EVP, Chief Scientific Officer at Inhibrx Biosciences, Inc..

Action: resigned
Role: EVP, Chief Scientific Officer

Exact text from the filing

On March 31, 2025, Brendan P. Eckelman, Ph.D. informed the Company of his intention to resign as EVP, Chief Scientific Officer of the Company, effective immediately, to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer.

View on SEC.gov

Inhibrx Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0002007919-25-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.